LFB symposium at the ISTH virtual congress on July 14th

LFB symposium at the ISTH virtual congress on July 14th

LFB holds a symposium during the ISTH congress, International Society on Thrombosis and Hemostasis, on July 14th. In the context of the international Covid-19 pandemic, this congress will be held virtually from July 12 to 14. This annual international congress is a key moment of exchange and a scientific meeting place for healthcare professionals specializing in haemostasis.

During the LFB symposium, Dr. Steven Pipe, professor at the University of Michigan (USA) and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and of the Special Coagulation Laboratory, will present the results of the PERSEPT-1 LFB’s study conducted with the recombinant activated Factor VII from LFB, approved by the FDA (USA) in early April, for the treatment of patients with hemophilia A and B with inhibitors

This symposium will also be an opportunity to take stock of Willebrand disease with Pr. Cédric Hermans, Head of the Haematology, Haemostasis and Thrombosis Unit and the Haemophilia Centre at the Saint-Luc University Hospital in Brussels, and Pr. Sophie Susen, Professor of Haematology, and Director of the Haemostasis and Transfusion Department at the Lille University Hospital. Following an updated review on the therapeutic care of Willebrand patients, supported by the results of the LFB’s Von Willebrand Factor post-marketing study, recently published in the Journal of Thrombosis & Hemostasis in May 2020, Pr. Cédric Hemans and Pr. Sophie Susen will give their perspectives on the plasma Willebrand Factor treatment.